We deliver end-to-end preclinical and clinical consulting that advances your innovation with scientific precision and commercial clarity. Our expertise spans nonclinical strategy, clinical development, regulatory documentation, and evidence generation to support investment and market entry. We design ICH-aligned preclinical programs and oversee CRO selection, contracting, GLP studies, and data interpretation. Our team builds IND/CTA-ready packages with strong scientific justification and clear risk-mitigation pathways.
We guide Phase I–III clinical strategy, protocol development, endpoint selection, and operational oversight.
Our regulatory support includes IND/CTA authoring, module integration, briefing documents, and agency responses.
We develop compelling evidence packages, conduct gap analyses, and map competitive differentiation for deal readiness.
Our advisory covers translational strategy, biomarkers, patient insights, lifecycle planning, and scientific communication.
Together, we ensure your program progresses efficiently, compliantly, and with strong commercial momentum.
Evidence-driven analytical excellence for pharmaceutical development
Robust analytical method development and validation following ICH guidelines for regulatory submission.
Comprehensive impurity profiling, identification, and characterization using advanced analytical techniques.
Long-term and accelerated stability studies with detailed analytical insights for shelf-life determination.
